Sun Pharmaceutical Industries Limited Press Release Sep 28 2026
Filed with NSE · · 6 pages · English
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Sun Pharma Launches (C)Taro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System
- First-Ever Standardized U.S. Treatment Recommendations Issued for Adults with Severe Alopecia Areata; Sun Pharma Welcomes Milestone
- Sun Pharma and Christian Siriano Launch "Regrowth Restyled" to Inspire Adults Living with Severe Alopecia Areata
- Sun Pharmaceutical Industries Limited Press Release Sep 01 2026
- Sun Pharmaceutical Industries Limited Press Release Jul 29 2026
Later from Sun Pharmaceutical Industries
- LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026".
- Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 20, 2026.
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 23, 2026.
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries